scispace - formally typeset
M

Majid Eslami

Researcher at Semnan University

Publications -  74
Citations -  1451

Majid Eslami is an academic researcher from Semnan University. The author has contributed to research in topics: Medicine & Immunology. The author has an hindex of 17, co-authored 57 publications receiving 805 citations. Previous affiliations of Majid Eslami include Tarbiat Modares University.

Papers
More filters
Journal ArticleDOI

Importance of probiotics in the prevention and treatment of colorectal cancer.

TL;DR: Research in clinical trials encouraging findings that support a role of probiotics in CRC prevention and improve the safety and effectiveness of cancer therapy even though additional clinical research is still necessary.
Journal ArticleDOI

Sensing properties of BN nanotube toward carcinogenic 4-chloroaniline: A computational study

TL;DR: In this article, the viability of using a BN nanotube for detection of a para-chloroaniline molecule was studied by means of density functional theory calculations, and it was shown that the Si-doped tube not only can adsorb the molecule strongly, but also may detect its presence because of the drastic increase of the electrical conductivity of the tube.
Journal ArticleDOI

Probiotics importance and their immunomodulatory properties

TL;DR: Some effects of modulation by probiotics include cytokine production by epithelial cells, increased mucin secretion, increased activity of phagocytosis, and activation of T and natural killer T cells, stimulation of immunoglobulin A production and decreased T cell proliferation.
Journal ArticleDOI

DNA nucleobase interaction with graphene like BC3 nano-sheet based on density functional theory calculations

TL;DR: In this paper, the interaction of various nucleobases (guanine (G), adenine (A), thymine (T) and cytosine (C)) with a graphene-like BC 3 nanosheet using dispersion corrected B3LYP level of theory was reported.
Journal ArticleDOI

A global treatments for coronaviruses including COVID-19.

TL;DR: A therapeutic window of drugs available to patients with coronavirus disease‐19 is reached and an ACE2 inhibitor and a clinical problem reducing agent such as favipiravir in addition to hydroxychloroquine and corticosteroids are reached.